Cargando…

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?

BACKGROUND: Regulatory and economic frameworks stimulated the research and development of orphan drugs, but very little has been done for devices necessary for the in-vivo diagnosis, prevention and treatment of life-threatening conditions with a low prevalence/incidence. DISCUSSION: A general public...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dooms, Marc M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778287/ https://www.ncbi.nlm.nih.gov/pubmed/26939863 http://dx.doi.org/10.1186/s13023-016-0393-3

Ejemplares similares

Orphan medical devices have come a long way
por: Dooms, M.
Publicado: (2023)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015)

How to START? Four pillars to optimally begin your orphan drug development
por: Jonker, Anneliene Hechtelt, et al.
Publicado: (2023)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
por: Heslop, Emma, et al.
Publicado: (2015)

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

Pharmacists are initiators in palliative care for patients with rare diseases
por: Dooms, M.
Publicado: (2023)

Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutions
por: Hulstaert, Frank, et al.
Publicado: (2023)

Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document()
por: Kumar, Saurabh, et al.
Publicado: (2020)

The mysterious orphans of Mycoplasmataceae
por: Tatarinova, Tatiana V., et al.
Publicado: (2016)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

The first European consensus on principles of management for achondroplasia
por: Cormier-Daire, Valerie, et al.
Publicado: (2021)

Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks
por: Hollak, Carla E. M., et al.
Publicado: (2016)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

Yesterday, Today and Tomorrow
por: CERN. Geneva
Publicado: (1993)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

European Association for the Study of Obesity Position Statement on the Global COVID-19 Pandemic
por: Frühbeck, Gema, et al.
Publicado: (2020)

European Achondroplasia Forum guiding principles for the detection and management of foramen magnum stenosis
por: Irving, Melita, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations
por: Cormier-Daire, Valerie, et al.
Publicado: (2022)

Together4RD position statement on collaboration between European reference networks and industry
por: Hedley, Victoria, et al.
Publicado: (2023)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS)
por: Kimmig, Rainer, et al.
Publicado: (2020)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild
por: Jara, P., et al.
Publicado: (2020)

Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity
por: Goossens, Gijs H., et al.
Publicado: (2020)

European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT)
por: Eker, Omer F., et al.
Publicado: (2020)

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability
por: Clayton-Smith, Jill, et al.
Publicado: (2019)

A post pandemic roadmap toward remote assessment for neuromuscular disorders: limitations and opportunities
por: Montes, Jacqueline, et al.
Publicado: (2022)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Directions for new developments on statistical design and analysis of small population group trials
por: Hilgers, Ralf-Dieter, et al.
Publicado: (2016)

Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
por: Moon, James C, et al.
Publicado: (2013)

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
por: Requena-Méndez, Ana, et al.
Publicado: (2020)

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023)

Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices
por: Herman, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ggil2gs3lhiir6l0lkemnc1hbn